Karran A. Phillips, MD, MSc NIDA Intramural Research Program AMERSA Annual Meeting November 8, 2014.

Slides:



Advertisements
Similar presentations
Aftercare Attendance Partially Moderated by History of Physical Abuse and Gender Louise F. Haynes 1 ; Amy E. Herrin 1 ; Rickey E. Carter 1 ; Sudie E. Back.
Advertisements

What is the evidence for time limiting addiction treatment?
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Swinomish Wellness Program
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
Addiction UNIT 4: PSYA4 Content The Psychology of Addictive Behaviour Models of Addictive Behaviour  Biological, cognitive and.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Journal Club Alcohol and Health: Current Evidence July-August 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse.
Addressing Crystal Methamphetamine Use Among Gay and Bisexual Men: A Treatment Center’s Response Joe Ruggiero, Ph.D. –Director, Outpatient Services The.
Practicalities of Conducting Biological Assessments for Drug Use Kenzie L. Preston, Ph.D. Chief, Clinical Pharmacology and Therapeutics Research Branch.
Copyright restrictions may apply A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
Low-Cost Contingency Management in Community Settings
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Substance Use Disorders: Treatment
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.
 Talks will be available at methodology.psu.edu.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Does reduction in cocaine use represent psychosocial benefit? Ivan D. Montoya, M.D., M.P.H. Deputy Director, NIDA-DPMC.
Impact of Online Counseling Farrokh Alemi, Ph.D..
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2012.
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
INTRODUCTION Many studies conducted in 1950’s and 1960’s suggest that hallucinogen assisted psychedelic psychotherapy may offer an effective treatment.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Harold I Perl, PhD National Institute on Drug Abuse APA 120 th Annual Convention August 3, 2012.
Raymond F. Anton, MD for The COMBINE Study Research Group
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
Patient and Staff Satisfaction in Outpatient Substance Abuse Treatment Programs A. Kulaga 1, B. McClure 1, J. Rotrosen 1, P. Crits-Christoph 2, S. Ring-Kurtz.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Reducing Sex under the Influence for Substance Abuse Treatment Patients Symposium Presentation at the American Psychological Association Annual Convention,
Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,
An fMRI Study of the Interaction of Stress and Cocaine Cues on Cocaine Craving in Cocaine-Dependent Men.
The Counseling Center, Inc. Devoted to the prevention and treatment of alcoholism and other drug addictions. We promote opportunities for individuals and.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Breast Cancer in the Women’s Health Initiative Trial of Estrogen Plus Progestin For the WHI Investigators Rowan T Chlebowski, MD., Ph.D.
1 Impact of Depression History on Tobacco Withdrawal and Relapse Among Female Smokers David W. Wetter, Ph.D. Department of Behavioral Science Funded by.
Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
Efficacy of a “One-Shot” Computerized, Individualized Intervention to Increase Condom Use and Decrease STDs among Clinic Patients with Main Partners Diane.
BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
VERSION VIII (i), August 14, 2003 BUPRENORPHINE/NALOXONE- FACILITATED REHABILITATION FOR OPIOID DEPENDENT ADOLESCENTS/YOUNG ADULTS PI: George E. Woody,
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Structured Physical Activity on Prevention.
Psychosocial Combined with Agonist Maintenance Treatments versus Agonist Maintenance Treatments Alone for Treatment of Opioid Dependence (Review) Amato,
Predictors of study retention in drug abuse treatment trials
Alcohol, Other Drugs, and Health: Current Evidence
EMA Outcome Measures in a Clinical Trial
Addiction in daily life: mobile assessment and treatment
Chair: Ingmar Franken, Netherlands
Room 1.09   Introduction to mobile assessments and treatment,
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
BACKGROUND & SIGNIFICANCE SUMMARY & FUTURE DIRECTIONS
Results: Specific Aim 2 (cont.)
Presentation transcript:

Karran A. Phillips, MD, MSc NIDA Intramural Research Program AMERSA Annual Meeting November 8, 2014

Effect of Clonidine on Response To Stress and Drug Cues Cocaine users not seeking treatment randomly assigned to:  Clonidine 0 mg (placebo)  Clonidine 0.1 mg  Clonidine 0.2 mg AdmissionDosingBaseline Measures Script Procedures10 min. Guided Relaxation Session 3 hours Behavioral Pharmacology Laboratory Studies Randomized Clinical Trials Archway - Outpatient Treatment Research Clinic Technology Development GPS – Real Time Location EMA – Real Time Self Report Geographical Momentary Assessment Treatment Section

Opiate agonists  effective treatments for opiate addiction  block drug cue reinstatement  no effect on stress-induced reinstatement  patients still relapse Alpha-2 agonists block stress-induced reinstatement possible effect on drug cue-induced reinstatement Is there a role for Alpha-2 agonists in Relapse Prevention?

Alpha-2 agonists for Relapse Prevention with buprenorphineIf we combine clonidine can we reduce time to lapse or relapse?

Randomized Clinical Trial Clonidine for Relapse Prevention Archway Clinic Clonidine 0 mg vs. 0.3 mg Opioid-dependent treatment seekers EMA Technology Development GPS – Real Time Location EMA – Real Time Self Report Geographical Momentary Assessment Relapse Prevention 11 9 C-I – clonidine induction Contingent Vouchers Maintenance Counseling Buprenorphine 5 21 (8-24 mg SL)/d weeks Clonidine Baseline Intervention Quit deadline Randomization Urine/breath/ 3 per week C-I 1

Environmental cues In the past hour did you see heroin? (yes/no) Right now, do you crave heroin? Stressors Right now, are you stressed? NO!! no?? yes?? YES!! Asked at four randomly prompted times during participant’s waking hours Ecological Momentary Assessment

Does clonidine prevent lapse? Time to Lapse - first opiate positive or missed urine Does it prevent relapse? Time to Relapse - any 2 or more consecutive positive or missed urines Cox regression Does it increase duration of abstinence? Longest period of consecutive opioid-negative urines 2-way ANOVA Statistical Analysis

Does clonidine decouple stress or cue exposure from craving? Probability of reporting heroin/opiate craving (either yes? or YES!!) from: Reports of stress Reports of seeing heroin in the past hour Generalized Linear Mixed Model (SAS PROC GLIMMX) Statistical Analysis

Results: Participants Placebo (n = 57) Clonidine (n = 61) M (SD) / n (%) Age (years) 38.3 (8.5)39.2 (7.8) Gender: Male46 (80.7%)46 (75.4%) Race: Black31 (54.4%)40 (65.6%) Education (years) 12.0 (2.0)11.9 (1.3) Heroin/Rx Opioid use (days in the last 30) 24.4 (7.9)25.1 (8.0) Cocaine use (days in the last 30) 3.4 (7.5)3.4 (7.3) # of drug treatments1.8 (1.8)1.7 (1.4)

Time to Lapse Time to Relapse – not significant; p =.71 Hazard ratio 1.09; 95% CI.70 – 1.67 Hazard ratio =.67 95% CI =.45 – 1.0 p =.05

Longest Duration of Continuous Abstinence t (109) =2.04, P≤0.05, Cohen’s d: * Individual participant

* Stress Rating Main effect of stress (F (3,257) =65.6, P≤0.001) EMA: Stress and Heroin Craving Likelihood of reporting heroin craving (%)

* Likelihood of reporting heroin craving (%) Stress Rating Main effect of Clonidine (F (1,105) =71.5, P≤ 0.001) 6.3% 11.8% EMA: Stress and Heroin Craving

* Stress Rating Drug X Stress interaction (F (3,257) =8.8, P≤0.001) EMA: Stress and Heroin Craving Likelihood of reporting heroin craving (%)

* Cue Exposure Did Not See Heroin Saw Heroin Main effect of exposure F (3,257) =65.6, P≤0.001 Main effect of clonidine F (3,257) =65.6, P≤0.001 EMA: Drug Cues and Heroin Craving Likelihood of reporting heroin craving (%) Drug x Exposure Interaction, p=n.s.

Does it work? Yes, clonidine given in conjunction with buprenorphine increased duration of abstinence and time to lapse. Does clonidine work in humans using the same mechanism as in animals? Evidence suggests yes. Stress and craving were decoupled by clonidine, while cue exposure and craving were not. Summary of Findings

For clinicians and patients: The EMA results identify the circumstances under which clonidine maintenance is most likely to be beneficial: exposure to moderate (though not severe) levels of daily-life stress. Discussion

For animal & human laboratory researchers: Our EMA results suggest that the seemingly contrived stressors used in the lab can indeed stand in for stressors encountered spontaneously by humans, outside the control of the investigator. Discussion

Kenzie Preston David Epstein Udi Ghitza Bill Kowalczyk Michelle Jobes Ashley Kennedy Daniel Agage John Schmittner Yavin Shaham Archway Staff and participants

Other Drug Use F (1,108) =6.32, P≤0.01, Cohen’s d=0.48 P=.40